Barclays analyst Peter Lawson sees positive read-through to Blueprint Medicines (BPMC) from Cogent Biosciences’ (COGT) abstract data for bezuclastinib in systemic mastocytosis. The data showed liver enzyme elevations leading to dose reductions and discontinuations, which could be a key differentiator given long duration of therapy in systemic mastocytosis, and efficacy potentially lower versus avapritinib, the analyst tells investors in a research note. The firm says that in advanced systemic mastocytosis efficacy favors Blueprint’s drug avapritinib. It has an Equal Weight rating on Blueprint shares with a $105 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BPMC:
- Blueprint should rally on today’s Cogent data, says Oppenheimer
- Blueprint Medicines price target lowered to $151 from $153 at Wells Fargo
- Blueprint Medicines Reports Strong Q3 2024 Results
- Blueprint management moves maybe made with buyer in mind, says Oppenheimer
- Blueprint Medicines reports Q3 EPS (89c), consensus (96c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
